OUTPACE Trademark

Trademark Overview


On Friday, January 17, 2025, a trademark application was filed for OUTPACE with the United States Patent and Trademark Office. The USPTO has given the OUTPACE trademark a serial number of 99007123. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Monday, July 7, 2025. This trademark is owned by Outpace Bio, Inc.. The OUTPACE trademark is filed in the Pharmaceutical Products category with the following description:

Medicines; drugs; pharmaceuticals; pharmaceutical preparations; therapeutics; therapeutic pharmaceuticals; therapeutic agents; cell therapies; biopharmaceuticals; medicines for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; drugs for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; pharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; pharmaceutical preparations for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic pharmaceuticals for use in the tr...
outpace

General Information


Serial Number99007123
Word MarkOUTPACE
Filing DateFriday, January 17, 2025
Status641 - NON-FINAL ACTION - MAILED
Status DateMonday, July 7, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesMedicines; drugs; pharmaceuticals; pharmaceutical preparations; therapeutics; therapeutic pharmaceuticals; therapeutic agents; cell therapies; biopharmaceuticals; medicines for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; drugs for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; pharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; pharmaceutical preparations for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic pharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; therapeutic agents for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologics for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologic preparations for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; cells for medical or clinical purposes; viral or non-viral delivery vectors for medical or clinical purposes; proteins for medical or clinical purposes; antibodies and libraries of antibodies for medical purposes; pharmaceutical preparations for cell therapy for medical or clinical purposes; targeted cell therapies; cell therapy products; gene therapy products; therapeutic antigens and antibodies; engineered cells; bioengineered cells; cell engineering platforms; protein design platforms; computational protein design platforms; AI-powered protein design platforms; pharmaceutical preparations developed with a computational protein design platform; pharmaceutical preparations developed with AI-powered protein design platforms; pharmaceutical preparations for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of cells, cell components, molecules, and viruses for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of gene delivery vectors for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of proteins for medical or clinical purposes, in particular for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders;

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, January 17, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameOutpace Bio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98109

Trademark Events


Event DateEvent Description
Friday, January 17, 2025NEW APPLICATION ENTERED
Friday, January 17, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 7, 2025NON-FINAL ACTION WRITTEN
Monday, July 7, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, July 7, 2025NON-FINAL ACTION E-MAILED
Friday, June 27, 2025ASSIGNED TO EXAMINER